The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
about
First line vs delayed transplantation in myeloma: Certainties and controversiesTowards Stratified Medicine in Plasma Cell MyelomaAdvances in understanding prognosis in myeloma.Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.Clonal heterogeneity of lymphoid malignancies correlates with poor prognosis.11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma.Engineering Multi-Walled Carbon Nanotube Therapeutic Bionanofluids to Selectively Target Papillary Thyroid Cancer Cells.Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.Utilizing next-generation sequencing in the management of multiple myeloma.Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?Which therapies will move to the front line for multiple myeloma?Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.Safety issues and management of toxicities associated with new treatments for multiple myeloma.The possible role of burden of therapy on the risk of myeloma extramedullary spread.Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland.Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.A three-drug combination to treat BRAF-mutant cancers.Triplet vs. doublet drug regimens for managing multiple myeloma.Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.Phenotypic Plasticity, Bet-Hedging, and Androgen Independence in Prostate Cancer: Role of Non-Genetic Heterogeneity.Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myelomaMultiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event
P2860
Q26745957-43D1A17E-46C5-401E-9DA1-D4101B9742B6Q28074994-C16FE2A3-E78D-4FA8-83F8-E1641602E392Q30244061-EC6CBF3C-1702-4A17-9E84-542F99D62D0EQ34556156-F7524FAD-F625-4E2D-B2EB-C8429D74E6CEQ35051842-5DD62413-43F2-49FA-8F97-8BBEF69229D6Q35781619-7A1EFF48-1B6C-4C33-8A84-8A03D39EE4DDQ35931194-A0598FEC-0028-4F17-A302-E8E18FD41FB5Q36306807-FE9410A0-CAB6-46CA-85DA-CB625EA98F6DQ38598891-AC673D36-37EE-4AB2-87CA-46233551947AQ38681814-685F7C23-F8CB-425C-A6B6-E92D4F469616Q38686915-4DF666B5-093F-40BC-B97B-33847824A8A8Q38728585-24238635-2993-4209-87A8-27689425C803Q38733592-AD799391-1680-49AF-B94E-D07C2C3CCFEEQ38764001-928F734D-08CD-4793-9DA7-119709D4516FQ38778519-20211D9A-323C-4510-852A-E1C42C26AAC3Q39100317-5BE054A9-1AEA-4711-99FA-B2AE868C0085Q39264310-DAE8917C-56AB-467F-80D1-0326C6640E08Q41810975-8F201ACB-9F7E-42E1-A49B-0728FB2DF430Q42181641-AB1BDA05-B8AE-4737-BAA6-B74725F0CF67Q46172410-98761D9F-98F2-42E9-8BFA-8030CE5126BAQ47770089-7D9DCD23-AE10-4595-AA7C-9DAF3ABDF6C4Q48236958-BC186890-20DF-4D36-BFF5-152C23CDA4FCQ53078069-F6A5CAA7-EF61-4D7B-A274-4F8312EC182AQ56967485-18998473-DEC8-4878-9472-30F8D3D3982CQ58754109-3F730C06-4BB7-42C2-80E1-BF383D4B21F9
P2860
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
@en
type
label
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
@en
prefLabel
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
@en
P2860
P50
P356
P1476
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma
@en
P2093
Lorenzo Melchor
P2860
P304
P356
10.1111/BJH.12805
P407
P577
2014-03-02T00:00:00Z